PharmExec

FEBRUARY 15, 2025

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Pharmacy Times

FEBRUARY 15, 2025

Data from the phase 2 CABRAMET trial suggests the potential of cabozantinib for treatment of brain metastases from renal cell carcinoma (RCC).

Patients 32

Patients 32

Pharmacy Times

FEBRUARY 15, 2025

C. Brooke Adams, PharmD, BCOP, discusses the evolving diagnostic criteria and management strategies for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy, highlighting advances in toxicity prevention and treatment selection.

Management 29

Management 29

Pharmacy Times

FEBRUARY 15, 2025

Enfortumab vedotin, trastuzumab deruxtecan, and disitamab vedotin were highlighted at the 2025 ASCO Genitourinary Cancers Symposium.

26

26

Advertiser: ZoomInfo

AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.

Sales

Pharmacy Times

FEBRUARY 15, 2025

A one-time infusion of etranacogene dezaparvovec-drlb led to sustained bleeding control and a reduction in factor IX prophylaxis in patients with hemophilia B.

Patients 26

Patients 26